Do Nootropics Actually Work? An Evidence Scorecard

Key takeaways

• We re-checked 84 verdicts from our September 2026 review of ingredient-page claims; 60 of them were claims about outcomes such as memory, attention, mood, sleep or physical performance.
• Of those 60 outcome claims, 22 were rated supported, 34 overstated, 1 contradicted, and for 3 our search found no human trial. Supported means the claim as worded matched the trials, including claims that an effect was small, mixed or absent.
• Caffeine had all four of its outcome claims rated supported. In a meta-analysis of seven randomized sleep-loss trials that included military personnel or military-related populations, caffeine significantly improved vigilance and response performance (SMD 0.73, 95% CI 0.50-0.96).
• Several of the positive trials we read enrolled older adults or people with a diagnosed condition such as mild cognitive impairment or Alzheimer's disease.
• The one outcome claim rated contradicted concerned phosphatidylserine in healthy children. In a 12-week trial of 100 mg a day of sunflower-derived phosphatidylserine in healthy children aged 8-12, there were no differences in the primary or secondary outcomes in the total cohort.
• This guide describes what trials measured and found. It does not say that any ingredient treats or prevents a disease.

New to the topic? What are nootropics? covers definitions, and Nootropics for beginners covers a careful first month. Safety is in Are nootropics safe?.

The short answer: it depends on the ingredient, the outcome and who was studied

Some nootropic ingredients do something measurable in some groups, and many claims go further than the trials. Ashwagandha, caffeine and DHA had every outcome claim rated supported, and citicoline, huperzine A, L-tyrosine, pine bark, rhodiola and Zynamite had none.

Supported means the trials we read backed the claim as worded; it does not mean large, and it does not mean the ingredient helps healthy people. So the useful question is not whether nootropics work. It is which claim, in which people, at which dose.

How we checked the claims

In September 2026 we reviewed the claims our ingredient pages made for 19 ingredients and recorded 84 verdicts. In October 2026 we re-checked each verdict against the primary studies, mostly by reading abstracts on PubMed; we did not read full texts. We treated the September files as leads, not as sources, and every study named below comes from a record we fetched. Each claim then received one of five labels:

• Supported: the trials we read back the claim as worded, in the group that was studied. This includes claims that an ingredient does not work.
• Overstated: the claim goes further than the trials we read, in size, in who was studied, in how many studies exist, or in what was measured.
• Understated: the trials we read show a larger or earlier effect than the claim states.
• Contradicted: a trial we read found the opposite of the claim, or a study the claim relies on is not what the claim says.
• No trial found: our search found no human trial testing this claim. This describes our search and does not show that no study exists.

Only outcome claims are counted: 60 of the 84 verdicts. The other 24 are excluded from every count: 7 mechanism, biomarker or other statements, 9 citation-accuracy claims, 5 safety claims, 3 timing claims and 0 dose claims. Our September review also had gaps: for 26 of the 84 verdicts the October re-check reached a different label.

The scorecard

The totals count outcome claims only, so they add up to 60.

• Supported: 22 of 60 outcome claims.
• Overstated: 34 of 60 outcome claims.
• Contradicted: 1 of 60 outcome claims.
• No trial found: 3 of 60 outcome claims.
• Understated: 0 of 60 outcome claims.

The table gives the supported count for each ingredient, a key finding with the group studied, and where claims went further. Most supported claims come first.

In the rows for Zynamite, oat straw, maritime pine bark and DHA, some studies tested a related product or the wider ingredient class; each cell names what the study used.

The studies we found for our Lutemax 2020 page tested related products: A meta-analysis of xanthophyll intake from foods or supplements found shorter photostress recovery (WMD -2.35, 95% CI -4.49 to -0.20). In 48 young adults with high screen time, 24 mg a day of macular carotenoids (lutein, zeaxanthin and mesozeaxanthin) improved eye strain versus placebo. In 70 screen users, Lute-gen (10 mg lutein, 2 mg zeaxanthin isomers) showed no between-group difference in the change in self-report measures.

Where the evidence is strongest

Caffeine had all four of its outcome claims rated supported, most of them about alertness and attention when people are short of sleep. A Cochrane review of 13 trials in people with jet lag or shift work disorder found better orientation and attention with caffeine (SMD -0.55; 95% CI -0.83 to -0.27), although none of the trials measured injuries. If your goal is memory rather than focus, see Nootropics for focus vs memory.

Claims that went further than the trials

Of the 60 outcome claims, 34 were rated overstated and 1 contradicted. The same patterns recur:

• Wrong population. Our page said alpha-GPC's memory effects were confirmed in healthy adults. In 261 people with mild to moderate Alzheimer's disease, choline alfoscerate (alpha-GPC) gave better ADAS-Cog and MMSE scores than placebo.
• A missing null result. Our page said no objective cognitive testing of methylliberine existed. In a 2023 trial of 25 healthy adults, methylliberine was tested with Stroop and Trail Making tests and had a negligible influence on cognitive function.
• Dose and study mismatch. Our page attached a Zynamite reaction-time result to 300 mg. The cited mango leaf extract study gave 500 mg in two trials of 16 people each. In 114 healthy adults aged 18-43, 300 mg of mango leaf extract significantly increased subtraction errors and had no other significant effects on cognitive performance.
• A safety omission. Our DHA copy did not mention atrial fibrillation. A meta-analysis of seven cardiovascular trials found a higher risk of atrial fibrillation with marine omega-3 supplements (HR 1.25, 95% CI 1.07-1.46), and a larger one above 1 g a day (HR 1.49, 95% CI 1.04-2.15). See Are nootropics safe?.

For three outcome claims our search found no human trial: Lion's Mane and nerve regeneration, methylliberine and tolerance, and Zynamite and n-back tasks.

Why results in healthy adults are often smaller or absent

Many of the positive results above come from people who started with a measurable problem, and results in healthy people look different.

• Phosphatidylserine: in a 6-month trial of 78 adults aged 50-69 with mild cognitive impairment, test scores rose in all groups including placebo; in those with relatively low baseline scores, memory scores rose significantly from baseline in the phosphatidylserine groups while the placebo group's stayed unchanged.
• Ginkgo: the 2026 Cochrane review found that at six months ginkgo may give small to moderate benefits in people with dementia (low-certainty evidence) and probably has little or no effect in mild cognitive impairment.
• Two ingredients showed null or negative results in people without a diagnosed condition. Bacopa: in 87 completers aged 40-70 with self-reported memory and attention problems, there were no between-group differences in the primary outcome measures. Tyrosine: in 70 healthy volunteers, 2.0 g of tyrosine worsened cognitive flexibility under the high cognitive load condition.

Placebo responses also matter. In the rhodiola burnout trial, burnout, mental-health and depression scores improved in both groups, and the authors label this a placebo effect.

Why studies of the same ingredient disagree

Several reasons recur in the abstracts we read.

• Dose. In an oat-herb crossover trial in older adults, 1,600 mg cut Stroop errors compared with 0 mg and 2,400 mg, so more was not better; a later trial in healthy adults aged 40-65 with self-reported memory decline suggested that the optimal dose lies at or below 800 mg.

What we do not know

• Long-term use. A 2022 review states that the long-term effects of nootropics on healthy individuals are still unknown, and the ashwagandha meta-analysis says further information is required to determine its safety with long-term administration.
• Products as sold. Some trials tested mixtures rather than single ingredients: a 12-month trial in 190 patients with mild cognitive impairment in Tianjin, China used capsules containing 144 mg alpha-linolenic acid, 31.5 mg phosphatidylserine, 3.6 mg ginkgo total flavonoids, 0.48 mg vitamin B1, 0.48 mg vitamin B6 and 90 μg folic acid, and a citicoline trial used a citicoline-caffeine beverage.

We did not read full texts, so details such as exact extracts, dropouts and statistical corrections may change a reading.

Are nootropics worth it? How to decide

Four questions help you decide.

1. Which claim am I paying for? Look for the outcome a trial measured, such as delayed recall, reaction time or a stress scale, not a general promise of focus.
2. Do I resemble the people studied? A result in adults with mild cognitive impairment or in sleep-deprived military personnel may not carry over to you.
3. What could go wrong? FDA states that, under the Dietary Supplement Health and Education Act, it does not have the authority to approve dietary supplements before they are marketed, and in Veterans Administration records, taking ginkgo concurrently with warfarin was associated with a hazard ratio of 1.38 (95% CI 1.20 to 1.58) for a bleeding event.
4. Can I test it fairly? Change one thing at a time, track one outcome, and compare against how you did before, as Nootropics for beginners explains.

Common questions

Do nootropics actually work? Some do, for some outcomes, in some groups. Of 60 outcome claims in our scorecard, 22 were rated supported and 34 overstated.

Are there any nootropics that actually work? The table shows which ingredients had supported claims and for whom. See Natural vs synthetic nootropics for how to compare options.

Do nootropics work for ADHD? This guide does not cover ADHD or any treatment claim. If you or your child have attention problems, talk to a clinician before using a supplement in place of or alongside other care.

Are nootropics good for you? Safety is separate from effectiveness; see Are nootropics safe?. What to expect and when is in What to expect from nootropics.